XML 27 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2019
Jun. 30, 2019
Current assets:    
Cash and cash equivalents $ 89.9 $ 93.2
Marketable investment securities 52.7 43.7
Prepaid expenses 14.0 16.6
Inventory 28.1 31.4
Trade accounts receivable 117.0 133.9
Prepaid taxes 23.0 25.1
Other receivables 4.8 4.7
Total current assets 329.5 348.6
Property, plant and equipment, net 55.0 57.3
Operating lease right-of-use assets 71.3  
Long-term marketable investment securities 51.5 54.9
Intangibles, net 667.8 684.7
Goodwill 416.1 417.2
Total assets 1,591.2 1,562.7
Current liabilities:    
Accounts payable 24.0 33.3
Accrued liabilities 73.0 78.9
Current maturities of operating lease liabilities 13.0  
Short-term contingent consideration 3.3 3.4
Deferred revenue 2.1 2.2
Total current liabilities 115.4 117.8
Unrecognized tax benefits 22.1 21.7
Noncurrent operating lease liabilities 62.6  
Other long-term liabilities 7.3 7.8
Contingent consideration 7.4 10.4
Long-term debt 225.0 233.5
Long-term deferred taxes 76.9 82.6
Total liabilities 516.7 473.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 74.4 and 73.5 shares outstanding at September 30, 2019 and June 30, 2019 respectively 0.7 0.7
Additional paid-in capital 1,076.3 1,068.0
Accumulated other comprehensive loss (7.5) (5.4)
Retained earnings 5.0 25.6
Total Myriad Genetics, Inc. stockholders’ equity 1,074.5 1,088.9
Total stockholders' equity 1,074.5 1,088.9
Total liabilities and stockholders’ equity $ 1,591.2 $ 1,562.7